{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T01:02:04Z","timestamp":1791939724854,"version":"4.3.4"},"reference-count":55,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T00:00:00Z","timestamp":1681776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Universidad Tecnol\u00f3gica de Pereira","award":["5-11-10"],"award-info":[{"award-number":["5-11-10"]}]},{"name":"Universidad Tecnol\u00f3gica de Pereira","award":["5-13-3"],"award-info":[{"award-number":["5-13-3"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Methadone treatment reduces the use of heroin and withdrawal symptoms; however, methadone is an expensive medication with a narrow safety margin. We compared the retention rates, persistence of heroin use, and quality of life of a group of patients undergoing conventional Methadone Maintenance Treatment (MMT) with a group for whom the CYP2B6 516G&gt;T polymorphism was used in addition to the MMT to calculate the required methadone dose. Over 12 weeks, the retention rate, heroin usage, and quality of life of patients under conventional treatment (n = 34) were compared with those of patients for whom we used genetic markers to calculate methadone dosage (n = 38). At the end of the study, 26.4% of patients abandoned the program, and neither demographic nor clinical variables were associated with treatment adherence. Of the remaining patients, 16% of the control group and 8% of patients in the pharmacogenetic group reported heroin use, while both groups showed a 64% reduction in the use of cocaine\/crack (no significant differences between the groups were found). Starting in the second week, the methadone dosage was lower among the patients for whom methadone was prescribed based on genotype. Although there were six individuals in the control group and three in the pharmacogenetic group with QTc intervals &gt; 450 ms (a threshold that is considered dangerous), we did not find a relationship between the QTc interval and methadone dosage. There were no differences in the perception of quality of life between the two groups. The results of this pilot study suggest that concerning methadone therapy, the CYP2B6 genotype contributes to reduced effective doses and treatment costs.<\/jats:p>","DOI":"10.3390\/life13041038","type":"journal-article","created":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T01:36:45Z","timestamp":1681781805000},"page":"1038","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Influence of CYP2B6 Genotype on Methadone Dosage in Patients from the Methadone Maintenance Treatment (MMT) Program in Pereira, Colombia"],"prefix":"10.3390","volume":"13","author":[{"given":"Carlos","family":"Isaza","sequence":"first","affiliation":[{"name":"Facultad de Ciencias de la Salud, Universidad Tecnol\u00f3gica de Pereira, Pereira 660003, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1071-6307","authenticated-orcid":false,"given":"Oscar Mauricio","family":"Casta\u00f1o-Ram\u00edrez","sequence":"additional","affiliation":[{"name":"Facultad de Ciencias de la Salud, Universidad de Caldas, Manizales 170004, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Pablo","family":"V\u00e9lez","sequence":"additional","affiliation":[{"name":"ESE Hospital Mental de Risaralda, Pereira 660001, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julieta","family":"Henao","sequence":"additional","affiliation":[{"name":"Facultad de Ciencias de la Salud, Universidad Tecnol\u00f3gica de Pereira, Pereira 660003, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6287-6815","authenticated-orcid":false,"given":"Leonardo","family":"Beltr\u00e1n-Angarita","sequence":"additional","affiliation":[{"name":"Facultad de Ciencias de la Salud, Universidad Tecnol\u00f3gica de Pereira, Pereira 660003, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5410-5997","authenticated-orcid":false,"given":"Juan Carlos","family":"Sep\u00falveda-Arias","sequence":"additional","affiliation":[{"name":"Grupo Infecci\u00f3n e Inmunidad, Facultad de Ciencias de la Salud, Universidad Tecnol\u00f3gica de Pereira, Pereira 660003, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,4,18]]},"reference":[{"key":"ref_1","unstructured":"Ministerio de Justicia y del Derecho (2022, October 22). Estudio Nacional de Consumo de Sustancias Psicoactivas. Colombia 2019, Available online: https:\/\/www.odc.gov.co\/Portals\/1\/publicaciones\/pdf\/estudioNacionaldeconsumo2019.pdf."},{"key":"ref_2","unstructured":"United Nations Office on Drugs and Crime (2022, October 22). World Drug Report. World Drug Report 2021. Available online: https:\/\/www.unodc.org\/unodc\/data-and-analysis\/wdr2021.html."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta11090","article-title":"Methadone and buprenorphine for the management of opioid dependence: A systematic review and economic evaluation","volume":"11","author":"Connock","year":"2007","journal-title":"Health Technol. Assess."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.3855\/jidc.4525","article-title":"Hepatitis B and C prevalence among heroin addicts in methadone maintenance treatment (MMT) and not in MMT in Pereira, Colombia","volume":"8","author":"Isaza","year":"2014","journal-title":"J. Infect. Dev. Ctries."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/10550887.2010.531672","article-title":"Effect of Methadone Maintenance Treatment on Heroin Craving, a Literature Review","volume":"30","author":"Fareed","year":"2011","journal-title":"J. Addict. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s11606-009-1225-0","article-title":"Methadone Deaths: Risk Factors in Pain and Addicted Populations","volume":"25","author":"Brooks","year":"2010","journal-title":"J. Gen. Intern. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/jcph.1","article-title":"Role of Cytochrome P4502B6 in Methadone Metabolism and Clearance","volume":"53","author":"Kharasch","year":"2013","journal-title":"J. Clin. Pharmacol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"755","DOI":"10.2217\/pgs.13.58","article-title":"Association of genetic variation in pharmacodynamic factors with methadone dose required for effective treatment of opioid addiction","volume":"14","author":"Levran","year":"2013","journal-title":"Pharmacogenomics"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.2217\/pgs.14.56","article-title":"Pharmacogenomics of methadone maintenance treatment","volume":"15","author":"Somogyi","year":"2014","journal-title":"Pharmacogenomics"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.rcp.2014.02.005","article-title":"Evaluaci\u00f3n del programa de mantenimiento con metadona del Hospital Mental de Risaralda","volume":"43","author":"Isaza","year":"2014","journal-title":"Rev. Colomb. Psiquiatr."},{"key":"ref_11","first-page":"145","article-title":"Pharmacogenomics biomarkers for personalized methadone maintenance treatment: The mechanism and its potential use","volume":"21","author":"Ramli","year":"2021","journal-title":"Bosn. J. Basic Med Sci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3389\/fgene.2013.00024","article-title":"Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): Advances on polymorphisms, mechanisms, and clinical relevance","volume":"4","author":"Zanger","year":"2013","journal-title":"Front. Genet."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/FPC.0b013e32835cb2e2","article-title":"Contribution of CYP2B6 alleles in explaining extreme (S)-methadone plasma levels: A CYP2B6 gene resequencing study","volume":"23","author":"Dobrinas","year":"2013","journal-title":"Pharm. Genom."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1097\/ALN.0000000000000867","article-title":"Methadone Pharmacogenetics: CYP2B6 Polymorphisms Determine Plasma Concentrations, Clearance, and Metabolism","volume":"123","author":"Kharasch","year":"2015","journal-title":"Anesthesiology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/JCP.0b013e318222b5dd","article-title":"CYP2B6 Polymorphisms Influence the Plasma Concentration and Clearance of the Methadone S-Enantiomer","volume":"31","author":"Wang","year":"2011","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1038\/s41598-022-07022-9","article-title":"CYP2B6 allelic variants and non-genetic factors influence CYP2B6 enzyme function","volume":"12","author":"Kiss","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"220","DOI":"10.52547\/ibj.25.3.220","article-title":"Investigating the CYP2B6 rs3745274 and rs3211371 polymorphisms in Methadone-Responder and Non-Responder Addicts in Iran","volume":"25","author":"Afjeh","year":"2021","journal-title":"Iran. Biomed. J."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Chawar, C., Hillmer, A., Lamri, A., Kapczinski, F., Thabane, L., Pare, G., and Samaan, Z. (2021). Implications of OPRM1 and CYP2B6 variants on treatment outcomes in methadone-maintained patients in Ontario: Exploring sex differences. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0261201"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.bbi.2008.05.010","article-title":"NIH public access policy","volume":"22","author":"Kelley","year":"2008","journal-title":"Brain Behav. Immun."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.drugalcdep.2011.01.008","article-title":"Predictors of methadone treatment retention from a multi-site study: A survival analysis","volume":"117","author":"Kelly","year":"2011","journal-title":"Drug Alcohol Depend."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"387","DOI":"10.7326\/0003-4819-150-6-200903170-00103","article-title":"QTc Interval Screening in Methadone Treatment","volume":"150","author":"Krantz","year":"2009","journal-title":"Ann. Intern. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"871","DOI":"10.2217\/pgs-2020-0040","article-title":"Pharmacogenomics of methadone: A narrative review of the literature","volume":"21","author":"Packiasabapathy","year":"2020","journal-title":"Pharmacogenomics"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"19","DOI":"10.25100\/cm.v44i1.1039","article-title":"Genetic variants associated with addictive behavior in Colombian addicted and non-addicted to heroin or cocaine","volume":"44","author":"Isaza","year":"2013","journal-title":"Colomb. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3109\/00952990.2011.649222","article-title":"Change in Quality of Life and Its Predictors in Heroin Users Receiving Methadone Maintenance Treatment in Taiwan: An 18-Month Follow-Up Study","volume":"38","author":"Wang","year":"2012","journal-title":"Am. J. Drug Alcohol Abus."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.pharmthera.2012.01.008","article-title":"Implications of central immune signaling caused by drugs of abuse: Mechanisms, mediators and new therapeutic approaches for prediction and treatment of drug dependence","volume":"134","author":"Coller","year":"2012","journal-title":"Pharmacol. Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1037\/adb0000090","article-title":"Predictors of patient retention in methadone maintenance treatment","volume":"29","author":"Proctor","year":"2015","journal-title":"Psychol. Addict. Behav."},{"key":"ref_27","first-page":"e29121","article-title":"Predictors of One-Year Retention in Methadone Maintenance Treatment (MMT) in Iran, Rafsanjan","volume":"5","author":"Fathollahi","year":"2016","journal-title":"Int. J. High Risk Behav. Addict."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.amjcard.2013.05.037","article-title":"QTc Interval Screening in an Opioid Treatment Program","volume":"112","author":"Katz","year":"2013","journal-title":"Am. J. Cardiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1089\/jpm.2016.0411","article-title":"Methadone and Corrected QT Prolongation in Pain and Palliative Care Patients: A Case\u2013Control Study","volume":"20","author":"Juba","year":"2017","journal-title":"J. Palliat. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/phar.2498","article-title":"Methadone-associated QT interval prolongation in patients undergoing maintenance therapy in an urban opioid treatment program","volume":"41","author":"Jaynes","year":"2021","journal-title":"Pharmacother. J. Hum. Pharmacol. Drug Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e23819","DOI":"10.5812\/ijhrba.4(2)2015.23819","article-title":"QTc Prolongation in Veterans With Heroin Dependence on Methadone Maintenance Treatment","volume":"4","author":"Hassamal","year":"2015","journal-title":"Int. J. High Risk Behav. Addict."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/fcp.12405","article-title":"QT length during methadone maintenance treatment: Gene \u00d7 dose interaction","volume":"33","author":"Zerdazi","year":"2018","journal-title":"Fundam. Clin. Pharmacol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/ADM.0000000000000353","article-title":"Methadone and the QTc Interval: Paucity of Clinically Significant Factors in a Retrospective Cohort","volume":"11","author":"Bart","year":"2017","journal-title":"J. Addict. Med."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Pani, P.P., Trogu, E., Maremmani, I., and Pacini, M. (2013). QTc interval screening for cardiac risk in methadone treatment of opioid dependence. Cochrane Database Syst. Rev., CD008939.","DOI":"10.1002\/14651858.CD008939.pub2"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1097\/ADM.0b013e3182a8a4f2","article-title":"Prospective Study of QTc Changes Among Former Opiate Addicts Since Admission to Methadone Maintenance Treatment: Benzodiazepine risk","volume":"7","author":"Peles","year":"2013","journal-title":"J. Addict. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/sj.clpt.6100120","article-title":"Stereoselective Block of hERG Channel by (S)-Methadone and QT Interval Prolongation in CYP2B6 Slow Metabolizers","volume":"81","author":"Eap","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.drugalcdep.2014.04.027","article-title":"KCNH2 polymorphism and methadone dosage interact to enhance QT duration","volume":"141","author":"Hajj","year":"2014","journal-title":"Drug Alcohol Depend."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s40291-017-0311-y","article-title":"Pharmacogenetics of Methadone Response","volume":"22","author":"Fonseca","year":"2018","journal-title":"Mol. Diagn. Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s40263-018-0513-9","article-title":"Pharmacogenetics of Opioid Use Disorder Treatment","volume":"32","author":"Crist","year":"2018","journal-title":"CNS Drugs"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Talal, A.H., Ding, Y., Venuto, C.S., Chakan, L.M., McLeod, A., Dharia, A., Morse, G.D., Brown, L.S., Markatou, M., and Kharasch, E.D. (2020). Toward precision prescribing for methadone: Determinants of methadone deposition. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0231467"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S0140-6736(07)61273-2","article-title":"Clinical update: Codeine maintenance in opioid dependence","volume":"370","author":"Hall","year":"2007","journal-title":"Lancet"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1124\/dmd.112.050625","article-title":"MethadoneN-Demethylation by the CommonCYP2B6Allelic Variant CYP2B6.6","volume":"41","author":"Gadel","year":"2013","journal-title":"Drug Metab. Dispos."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Dennis, B.B., Bawor, M., Thabane, L., Sohani, Z., and Samaan, Z. (2014). Impact of ABCB1 and CYP2B6 Genetic Polymorphisms on Methadone Metabolism, Dose and Treatment Response in Patients with Opioid Addiction: A Systematic Review and Meta-Analysis. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0086114"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1369-1600.2011.00349.x","article-title":"CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction","volume":"18","author":"Levran","year":"2013","journal-title":"Addict. Biol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.2217\/pgs.11.96","article-title":"Impact of genetic polymorphisms in ABCB1, CYP2B6, OPRM1, ANKK1 and DRD2 genes on methadone therapy in Han Chinese patients","volume":"12","author":"Hung","year":"2011","journal-title":"Pharmacogenomics"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.clpt.2005.08.011","article-title":"Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment","volume":"78","author":"Crettol","year":"2005","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Fonseca, F., De La Torre, R., D\u00edaz, L., Pastor, A., Cuy\u00e0s, E., Pizarro, N., Khymenets, O., Farr\u00e9, M., and Torrens, M. (2011). Contribution of Cytochrome P450 and ABCB1 Genetic Variability on Methadone Pharmacokinetics, Dose Requirements, and Response. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0019527"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.2217\/pgs.11.103","article-title":"Genetic polymorphisms in CYP3A4 are associated with withdrawal symptoms and adverse reactions in methadone maintenance patients","volume":"12","author":"Chen","year":"2011","journal-title":"Pharmacogenomics"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1186\/1471-244X-13-190","article-title":"Improvement of quality of life in methadone treatment patients in northern Taiwan: A follow-up study","volume":"13","author":"Chou","year":"2013","journal-title":"BMC Psychiatry"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Gottlieb, A., Bakos-Block, C., Langabeer, J.R., and Champagne-Langabeer, T. (2022). Sociodemographic and Clinical Characteristics Associated with Improvements in Quality of Life for Participants with Opioid Use Disorder. Healthcare, 10.","DOI":"10.3390\/healthcare10010167"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.drugpo.2012.09.005","article-title":"Profiles of quality of life in opiate-dependent individuals after starting methadone treatment: A latent class analysis","volume":"24","author":"Bongers","year":"2013","journal-title":"Int. J. Drug Policy"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.jsat.2005.08.002","article-title":"Patterns of heroin, cocaine, and alcohol abuse during long-term methadone maintenance treatment","volume":"29","author":"Meili","year":"2005","journal-title":"J. Subst. Abus. Treat."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e015875","DOI":"10.1136\/bmjopen-2017-015875","article-title":"Concurrent drug use among methadone maintenance patients in mountainous areas in northern Vietnam","volume":"8","author":"Tran","year":"2018","journal-title":"BMJ Open"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Di Nunno, N., Esposito, M., Argo, A., Salerno, M., and Sessa, F. (2021). Pharmacogenetics and Forensic Toxicology: A New Step towards a Multidisciplinary Approach. Toxics, 9.","DOI":"10.3390\/toxics9110292"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Almeida-Gonz\u00e1lez, M., Boada, L.D., Burillo-Putze, G., Henr\u00edquez-Hern\u00e1ndez, L.A., Luzardo, O.P., Quintana-Montesdeoca, M.P., and Zumbado, M. (2023). Ethanol and Medical Psychotropics Co-Consumption in European Countries: Results from a Three-Year Retrospective Study of Forensic Samples in Spain. Toxics, 11.","DOI":"10.3390\/toxics11010045"}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/13\/4\/1038\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:17:49Z","timestamp":1760123869000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/13\/4\/1038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,18]]},"references-count":55,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["life13041038"],"URL":"https:\/\/doi.org\/10.3390\/life13041038","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,18]]}}}